Deliberations about clinical pharmacogenetic testing in pediatric oncology

Amalia M Issa; Sarah Ae Aboushawareb; David D Eisenstat; Greg Mt Guilcher; Geoffrey Liu; S Rod Rassekh; Caron Strahlendorf; Gesche Tallen; Reo Tanoshima; Bruce Carleton

doi:10.2217/pme-2020-0120

Deliberations about clinical pharmacogenetic testing in pediatric oncology

Per Med. 2021 Jul;18(4):399-405. doi: 10.2217/pme-2020-0120. Epub 2021 May 11.

Authors

Amalia M Issa^{1

2

3

4}, Sarah Ae Aboushawareb⁴, David D Eisenstat^{5

6}, Greg Mt Guilcher^{7

8}, Geoffrey Liu⁹, S Rod Rassekh^{10

11

12}, Caron Strahlendorf^{10

11

12}, Gesche Tallen^{7

13}, Reo Tanoshima^{14

15}, Bruce Carleton¹⁰

Affiliations

¹ Personalized Precision Medicine & Targeted Therapeutics Institute, PA 19064, USA.
² Departments of Pharmaceutical Sciences and Health Policy, University of The Sciences in Philadelphia, Philadelphia, PA 19104, USA.
³ Centre of Genomics & Policy, McGill University, Montreal, Quebec H3A 0G1, Canada.
⁴ Department of Family Medicine, McGill University, Montreal, Quebec H3S 1Z1, Canada.
⁵ Department of Paediatrics, Murdoch Children's Research Institute, University of Melbourne, Melbourne 3052, Australia.
⁶ Departments of Pediatrics, Medical Genetics & Oncology, University of Alberta, Edmonton AB T6G 2H7, Canada.
⁷ Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta T3B 6A8, Canada.
⁸ Department of Oncology, University of Calgary, Calgary AB T2N 4N1, Canada.
⁹ Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto ON M5G 2C1, Canada.
¹⁰ Department of Pediatrics & BC Children's Hospital Research Institute, Division of Translational Therapeutics, University of British Columbia, Vancouver, BC V6H 3V4, Canada.
¹¹ YCU Center for Novel & Exploratory Clinical Trials, Yokohama City University, Yokohama, Kanagawa 236-0004, Japan.
¹² Department of Pediatrics, University of British Columbia, Vancouver, BC V6H 3V4, Canada.
¹³ Pediatric Hematology/Oncology/BMT, BC Children's Hospital, Vancouver BC V6H 3V4, Canada.
¹⁴ Department of Pediatric Oncology/Hematology, Charité-Medical School Charitéplatz 1, Berlin 10117, Germany.
¹⁵ Department of Pediatrics, Yokohama City University, Yokohama, Kanagawa 236-0004, Japan.

PMID: 33973801
DOI: 10.2217/pme-2020-0120

Abstract

This article summarizes the background, content and outcomes of a special meeting that was convened among oncologists and scientists to discuss the role of pharmacogenetic (PGx) testing in pediatric clinical oncology practice. This meeting provided an opportunity for what the lead author (AM Issa) refers to as the 'voice of the clinician' dynamic to be amplified in order to better understand how personalized or precision medicine applications such as PGx testing are adopted and incorporated into clinical settings and what we can learn from the experiences of current and ongoing implementation PGx approaches to further the implementation of precision medicine applications in real-world environments. Group dynamics and clinical experience with PGx testing and return of results shaped the discussion.

Keywords: adverse reactions; deliberative consultation; oncologists; pediatric oncology; personalized medicine; pharmacogenetics; pharmacogenomics; precision medicine; special meeting report; translational research.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Child
Humans
Medical Oncology
Neoplasms* / drug therapy
Neoplasms* / genetics
Pharmacogenetics*
Pharmacogenomic Testing
Precision Medicine

Grants and funding

GP1-155872/CIHR/Canada